IMVARIA is a health tech company pioneering AI-driven digital biomarker solutions that empower clinicians to make accurate diagnoses and prognoses at earlier stages of disease and reduce the need for invasive biopsy testing. Founded in 2019 by physician-engineers from Google and Stanford University, the company operates its AI Lab with automated, machine-learning algorithm technology to transform clinical decision-making into data science. IMVARIA is based in Berkeley, CA.

IMVARIA is a software-as-medical-device (SaMD) company pioneering AI-driven digital biomarker solutions that help clinicians make accurate diagnoses and prognoses at earlier stages of disease, potentially reducing the need for invasive biopsy testing. Their solutions include FDA-authorized tools such as Fibresolve and ScreenDx for lung diseases like interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF). The company collaborates with institutions like Mayo Clinic and focuses on transforming clinical decision-making through AI and machine learning technologies.

IMVARIA's leadership includes co-founders Dr. Joshua Reicher (CEO) and Dr. Michael Muelly (CTO), both physician-engineers with backgrounds at Google and Stanford. The company supports clinicians, health systems, and biopharmaceutical partners through its AI Lab, offering cloud-based analysis and insights for clinical diagnostics and therapeutic development. IMVARIA maintains a remote-first work culture and is actively growing engineering and commercial teams.